Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery offers an approach for gastric cancer patients facing peritoneal metastasis, though its exact role within multimodal management remains widely debated, according to a literature review published in Cureus. Peritoneal metastasis affects roughly 30 percent of advanced gastric cancer patients and carries a poor prognosis, with untreated median survival often limited to approximately three months.
Understanding Peritoneal Metastasis in Gastric Cancer
Gastric cancer ranks as the sixth most common cancer globally and the fourth leading cause of cancer death, according to data cited in a clinical case report published on PubMed Central (PMC). Peritoneal carcinomatosis accounts for roughly 35 percent of all synchronous metastases in these patients. Standard systemic chemotherapy frequently yields limited effectiveness against disease restricted to the peritoneal cavity. Because conventional treatments struggle to reach tumors in the peritoneal lining, specialists utilize regional surgical interventions to address local spread.
The Mechanics of Cytoreductive Surgery and HIPEC
Cytoreductive surgery aims to remove all visible tumor nodules from the abdominal cavity through the resection of involved organs and peritonectomy procedures, following principles established by surgical pioneer Dr. Paul Sugarbaker, as noted in the PMC case report. Immediately following this resection, hyperthermic intraperitoneal chemotherapy delivers heated chemotherapy directly into the abdomen. The procedure circulates warmed chemotherapy solutions to eliminate microscopic residual cancer cells while enhancing drug penetration through hyperthermia.
Prophylactic Versus Therapeutic Applications
Clinical investigations evaluate hyperthermic intraperitoneal chemotherapy in two distinct clinical settings: therapeutic treatment for established peritoneal metastasis and prophylactic administration for patients at high risk of developing peritoneal recurrence. A meta-analysis of randomized controlled trials conducted by Granieri et al. in 2021, referenced in the Cureus study review, indicates that combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy benefits patients in both settings. Despite these findings, major national oncology guidelines do not uniformly mandate the procedure as standard care for gastric cancer.
Protocol Variations and Current Research Challenges
Analyzing 50 studies encompassing 3,946 patients, researchers publishing in Cureus highlighted several variables that complicate clinical consensus. Investigators emphasize that medical centers must standardize treatment duration, ensuring the shortest effective exposure time for hyperthermic intraperitoneal chemotherapy. Furthermore, protocols require consistent drug concentrations, matching liquid solvents, and precise documentation of perioperative chemotherapy regimens. Establishing a universal definition for surgical morbidity remains a priority for future clinical trials aiming to improve patient selection and survival outcomes.